-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67

Benzinga·11/04/2026 23:35:03
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.